Fourth-quarter gross margin was 75%, up 45 basis points year over year, driven primarily by favorable product mix. AtriCure reported fourth-quarter net income of $1.8 million versus a $15.6 million net loss a year earlier, and adjusted EBITDA of $19.9 million versus $12.7 million in 2024. EPS was $0.04 and adjusted EPS was $0.06, compared with a loss per share of $0.33 and adjusted loss per share of $0.08 in the prior-year quarter.In the fourth quarter, worldwide revenue was $140.5 million, increasing 13.1% ...

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAngie Wirick - CFODanny Stauder - Director of Equity Research in Medical TechnologyJohn McAulay - Associate VPMarissa Bych - Managing DirectorMike Carrel - President and CEOConference Call ParticipantsLily Lozada - Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMike Matson - Senior AnalystSuraj Kalia - Managing Director and Senior Analyst in Medical Tec ...

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Speaker10Good afternoon, and welcome to AtriCure's fourth quarter and full year 2025 earnings conference call. This call is being recorded for replay purposes, and at this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session following prepared remarks from AtriCure's management. I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory com ...